Elicio Therapeutics Announces $10.0 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
30. Januar 2025 08:00 ET
|
Elicio Therapeutics Inc.
BOSTON, Jan. 30, 2025 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio Therapeutics” or “Elicio”), a clinical-stage biotechnology company developing a pipeline of novel...
Elicio Therapeutics Reaches Alignment with FDA on ELI-002 Registrational Strategy
22. Januar 2025 07:30 ET
|
Elicio Therapeutics Inc.
Received supportive FDA feedback on key elements of the potential ELI-002 Phase 3 study design, including dose, schedule, patient population and primary endpoint analysis Phase 2 randomized study of...
Elicio Therapeutics Presents Updated Results from ELI-002 Phase 1 AMPLIFY-201 Study at ESMO Immuno-Oncology Congress 2024
12. Dezember 2024 07:00 ET
|
Elicio Therapeutics Inc.
Updated Phase 1 data include a 16.3-month median recurrence-free survival (“mRFS”) and 28.9-month median overall survival (“mOS”) from full study population Strong correlation observed between mRFS...
Elicio Therapeutics Announces Completion of Phase 2 AMPLIFY-7P Study Enrollment
03. Dezember 2024 07:00 ET
|
Elicio Therapeutics Inc.
BOSTON, Dec. 03, 2024 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio Therapeutics” or “Elicio”), a clinical-stage biotechnology company developing a pipeline of novel...
Elicio Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Updates
13. November 2024 16:05 ET
|
Elicio Therapeutics Inc.
AMPLIFY-7P Phase 2 randomized study anticipated to complete enrollment in Q4 2024; formal interim analysis of disease-free survival (“DFS”) expected in H1 2025Poster presentation at the Society for...
Elicio Therapeutics Presents Updated Translational Data from ELI-002 Phase 1 AMPLIFY-7P Study at the Society for Immunotherapy of Cancer (“SITC”) 2024 Annual Meeting
07. November 2024 16:05 ET
|
Elicio Therapeutics Inc.
Preliminary data demonstrate durable and dose-dependent T cell responses targeting KRAS mutations and induced responses to patient-specific neoantigens Correlation observed between disease-free...
Elicio Therapeutics to Present Clinical Data at the Society for Immunotherapy of Cancer (SITC) 2024 Annual Meeting and Stand Up to Cancer (SU2C) Innovation Summit
31. Oktober 2024 08:30 ET
|
Elicio Therapeutics Inc.
Poster presentation at SITC to highlight extended follow-up data from AMPLIFY-7P Phase 1 study Oral presentation at SU2C Innovation Summit to highlight data from AMPLIFY-7P and AMPLIFY-201 Phase 1...
Elicio Therapeutics Reports Inducement Grants
16. Oktober 2024 08:30 ET
|
Elicio Therapeutics Inc.
BOSTON, Oct. 16, 2024 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio Therapeutics” or “Elicio”), a clinical-stage biotechnology company developing a pipeline of novel...
Elicio Therapeutics Reports Inducement Grants
17. September 2024 08:31 ET
|
Elicio Therapeutics Inc.
BOSTON, Sept. 17, 2024 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio Therapeutics” or “Elicio”), a clinical-stage biotechnology company developing a pipeline of novel...
Elicio Therapeutics Announces Three Upcoming Presentations Focused on its Lymph Node Targeted, mKRAS-Specific Amphiphile Vaccines
13. September 2024 08:30 ET
|
Elicio Therapeutics Inc.
BOSTON, Sept. 13, 2024 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio Therapeutics” or “Elicio”), a clinical-stage biotechnology company developing a pipeline of novel...